NanoPhoria has achieved second place in the Start-up category of the “I protagonisti dell’innovazione” award, an initiative from INNLIFES that aims to recognise individuals and companies who during 2025, generated significant innovation in the Italian Life Sciences sector, including healthcare professionals, startups, investors, and incubators.

During 2025, NanoPhoria closed a Series A financing round of €83.5 million, led by XGen Venture, Sofinnova Partners and CDP Venture Capital, supporting the advancement of its therapeutic pipeline and platform technology. This marked the largest ever series A funding round in Italian biotech.

Speaking on the award, NanoPhoria CEO, Claudio De Luca said: “Receiving recognition for all our hard work at NanoPhoria serves as encouragement to continue. We believe that our innovative drug delivery platform, which utilises a novel Nano-in-Micro technology to deliver powerful therapeutics directly to the heart, will have a positive impact on the live of millions of patients worldwide. As we continue to advance towards the clinic, we look forward to publishing more data proving out what we are working on.

About NanoPhoria

Founded in 2022 by Daniele Catalucci, Michele Iafisco, Alessio Alogna and Claudio De Luca NanoPhoria is a spin-off from Italy’s National Research Council (CNR). The company is developing a versatile, Nano-in-Micro & lung-to-heart delivery platform based on inorganic calcium phosphate nanoparticles. The company’s first product is a pre-clinical stage treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide. NanoPhoria is supported by Sofinnova Partners, XGEN Venture, CDP Venture Capital and other investors. Learn more at NanoPhoria.com